Sartorius Stedim Biotech S.A. (DIM.PA)
EUR 188.3
(1.02%)
EUR 188.3
(1.02%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 777.2 Million EUR | -41.41% |
| 2022 | 1.35 Billion EUR | 49.41% |
| 2021 | 811.95 Million EUR | 32.23% |
| 2020 | 623.79 Million EUR | 49.6% |
| 2019 | 410.74 Million EUR | 22.74% |
| 2018 | 360.07 Million EUR | 13.55% |
| 2017 | 279.59 Million EUR | 6.75% |
| 2016 | 270.91 Million EUR | 26.36% |
| 2015 | 225.9 Million EUR | 41.99% |
| 2014 | 152.85 Million EUR | 17.0% |
| 2013 | 129.05 Million EUR | 12.03% |
| 2012 | 113.35 Million EUR | 23.35% |
| 2011 | 91.1 Million EUR | 15.98% |
| 2010 | 83.3 Million EUR | 16.27% |
| 2009 | 71.64 Million EUR | 29.72% |
| 2008 | 50 Million EUR | 88.72% |
| 2007 | 29.26 Million EUR | -55.19% |
| 2006 | 65.31 Million EUR | 21.36% |
| 2005 | 53.81 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 149.6 Million EUR | -21.96% |
| 2024 Q1 | 183.6 Million EUR | 6.18% |
| 2024 Q2 | 187.3 Million EUR | -2.19% |
| 2023 Q2 | 236.1 Million EUR | 8.5% |
| 2023 Q1 | 217.6 Million EUR | -20.09% |
| 2023 Q4 | 108.1 Million EUR | -29.35% |
| 2023 Q3 | 153 Million EUR | -35.2% |
| 2023 FY | - EUR | -41.41% |
| 2022 FY | - EUR | 49.41% |
| 2022 Q4 | 272.3 Million EUR | -17.91% |
| 2022 Q1 | 389.5 Million EUR | 1063.59% |
| 2022 Q2 | 337.2 Million EUR | -13.43% |
| 2022 Q3 | 331.7 Million EUR | -1.63% |
| 2021 FY | - EUR | 32.23% |
| 2021 Q1 | 238.6 Million EUR | 51.94% |
| 2021 Q4 | 33.47 Million EUR | -87.74% |
| 2021 Q3 | 273.1 Million EUR | 7.65% |
| 2021 Q2 | 253.7 Million EUR | 6.33% |
| 2020 FY | - EUR | 49.6% |
| 2020 Q2 | 131.6 Million EUR | 2.65% |
| 2020 Q1 | 128.2 Million EUR | 44.95% |
| 2020 Q4 | 157.03 Million EUR | -10.78% |
| 2020 Q3 | 176 Million EUR | 33.74% |
| 2019 Q1 | 95.7 Million EUR | -6.14% |
| 2019 FY | - EUR | 22.74% |
| 2019 Q4 | 88.44 Million EUR | -14.54% |
| 2019 Q3 | 103.5 Million EUR | -2.27% |
| 2019 Q2 | 105.9 Million EUR | 10.66% |
| 2018 Q3 | 89 Million EUR | 3.49% |
| 2018 Q2 | 86 Million EUR | 22.16% |
| 2018 Q1 | 70.4 Million EUR | 6.33% |
| 2018 Q4 | 101.95 Million EUR | 14.56% |
| 2018 FY | - EUR | 13.55% |
| 2017 Q3 | 67.5 Million EUR | 16.58% |
| 2017 Q4 | 66.21 Million EUR | -1.91% |
| 2017 Q1 | 69.9 Million EUR | -5.67% |
| 2017 FY | - EUR | 6.75% |
| 2017 Q2 | 57.9 Million EUR | -17.17% |
| 2016 Q1 | 61.1 Million EUR | 0.37% |
| 2016 FY | - EUR | 26.36% |
| 2016 Q4 | 74.1 Million EUR | -0.8% |
| 2016 Q3 | 74.7 Million EUR | 25.76% |
| 2016 Q2 | 59.4 Million EUR | -2.78% |
| 2015 FY | - EUR | 41.99% |
| 2015 Q1 | 50.3 Million EUR | 26.68% |
| 2015 Q4 | 60.87 Million EUR | -7.62% |
| 2015 Q3 | 65.9 Million EUR | 43.57% |
| 2015 Q2 | 45.9 Million EUR | -8.75% |
| 2014 Q3 | 39.2 Million EUR | 28.52% |
| 2014 FY | - EUR | 17.0% |
| 2014 Q1 | 32.6 Million EUR | 0.49% |
| 2014 Q2 | 30.5 Million EUR | -6.44% |
| 2014 Q4 | 39.7 Million EUR | 1.29% |
| 2013 Q4 | 32.44 Million EUR | 4.31% |
| 2013 FY | - EUR | 12.03% |
| 2013 Q1 | 28.5 Million EUR | -12.2% |
| 2013 Q2 | 30.7 Million EUR | 7.72% |
| 2013 Q3 | 31.1 Million EUR | 1.3% |
| 2012 Q4 | 32.46 Million EUR | 0.0% |
| 2012 Q2 | 23.2 Million EUR | 0.0% |
| 2012 FY | - EUR | 23.35% |
| 2011 FY | - EUR | 15.98% |
| 2011 Q2 | 17.6 Million EUR | 0.0% |
| 2010 FY | - EUR | 16.27% |
| 2010 Q2 | 16.8 Million EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2009 FY | - EUR | 29.72% |
| 2008 FY | - EUR | 88.72% |
| 2007 FY | - EUR | -55.19% |
| 2006 FY | - EUR | 21.36% |
| 2005 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Crossject Société Anonyme | -7.29 Million EUR | 10752.412% |
| Safe Orthopaedics SA | -5.62 Million EUR | 13919.346% |
| Spineway SA | -4.79 Million EUR | 16322.083% |
| Amplitude Surgical SA | 24.72 Million EUR | -3042.996% |
| EssilorLuxottica Société anonyme | 6.18 Billion EUR | 87.426% |
| bonyf N.V. | -39.89 Thousand EUR | 1948258.236% |